Recent announcements
POINT Biopharma Unveils FRONTIER: A Pan-Cancer FAP-α Targeted Clinical Program
A No-Objection Letter from Health Canada has been received, enabling the initiation of PNT2004’s Phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy.
POINT Biopharma Reports First Quarter 2022 Financial Results and Provides Business Update
POINT's manufacturing facility initiated supply for the Phase 3 SPLASH trial. Randomization of patients for the SPLASH trial expanded to the European Union as scheduled. CTA filed with Health Canada for Phase 1 therapeutic trial for PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha (FAP-alpha) targeted program; trial is expected to commence this summer.
POINT Biopharma Confirms No Supply Shortages of 177Lu-PNT2002 for the SPLASH Trial
Clinical doses continue to be manufactured and shipped from the Company’s Indianapolis, Indiana facility
First European Union Patient Dosed with 177Lu-PNT2002 in the Phase 3 SPLASH Trial
POINT Biopharma’s Phase 3 SPLASH trial in pre-chemo metastatic castration-resistant prostate cancer (mCRPC) is now randomizing in the US, Canada, and Europe. Sites initiated in France, Sweden, Netherlands, and the UK, with randomization in each expected this summer.
POINT Biopharma to Present on its Pan-Cancer FAP-Alpha Targeted Program at the AACR Annual Meeting
POINT’s PNT6555 is a potent and specific inhibitor of Fibroblast Activation Protein (FAP), a phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy is planned for summer 2022
POINT Biopharma Reports Fiscal 2021 Financial Results and Provides Business Update
Reported 27-patient dosimetry data from the lead-in cohort of the SPLASH trial. Randomization phase of SPLASH trial ongoing, top line data expected mid-2023. Phase 1 therapeutic trial for PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha (FAP-alpha) inhibitor program, planned for summer 2022. Indianapolis radiopharmaceutical manufacturing facility operational and supplying doses of PNT2002 to support the SPLASH trial – view the facility online at manufacturing.pointbiopharma.com.
POINT Biopharma Confirms No Delays to SPLASH Trial Due to Recent Global Lutetium Supply Interruption
POINT’s industry-leading radioisotope supply chain enabled company to avoid delays
POINT Biopharma to Host Dosimetry Investor Education Event on March 29, 2022
Learn what “PNT2002 has a favorable and safe dosimetry profile in the patient population and dose regimen being studied” means in the context of radiopharmaceuticals. Register online at https://hub.pointbiopharma.com/dosimetry